Article info

Download PDFPDF

Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA

Authors

  1. Correspondence to Mr Michael Ingham; mingham2{at}its.jnj.com
View Full Text

Citation

Singhal M, Tan H, Coleman CI, et al
Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA

Publication history

  • Received June 3, 2019
  • Revised September 18, 2019
  • Accepted September 24, 2019
  • First published November 7, 2019.
Online issue publication 
November 07, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.